Forecast
The analysts' average price target is €42.23 (+415.00%). The median is €43.76 (+433.66%).
| Buy |
Â
10 |
| Hold |
Â
4 |
| Sell |
Â
1 |
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
In the last quarter, DBV Technologies (ADR) had revenue of €0 and net profit of -€56.94M
| (EUR) | September 2026 | YoY |
|---|---|---|
| Revenue | 0 | - |
| Gross profit | 0 | 100.00% |
| Net profit | -56.94M | 102.40% |
| EBITDA | -54.03M | 101.31% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €205.42M |
Number of shares | 23.92M |
52-week high/low | €23.87 - €7.87 |
| Dividends | No |
Beta | -0.21 |
P/E ratio | -3.25 |
PEG ratio | -0.05 |
P/B ratio | 6.01 |
P/S ratio | 106.78 |
Company profile
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The milk-induced company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA); Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.
| Name | DBV Technologies (ADR) |
| CEO | Daniel Tassé |
| Website | |
| IPO | 10/22/2014 |
| Employees | 125 |